Quantcast

Latest tumor Stories

2014-06-02 08:29:15

Combined Gene and Protein Analysis of Sarcoma Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 2, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced the presentation of data from a study in which multiplatform biomarker assessment was used to identify multiple potential novel targets for the treatment of sarcoma, a type of cancer that begins in bone or in the...

2014-06-01 08:20:22

Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data at the 50th Annual Meeting of ASCO in which molecular profiling identified numerous potential drug options in patients with various types of gastrointestinal (GI) cancer. Among...

2014-05-31 08:20:38

Clinical Studies in Gynecologic Cancers Confirm the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, May 31, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian...

2014-05-30 08:25:19

Validation Data on More Than 300 Patients to be Released at the 2014 American Society of Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., May 30, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, announced today that its premier product, Guardant360(TM) is now widely commercially available following recent successful introduction to early access partners....

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-20 23:08:25

Barnes-Jewish Hospital was one of the first hospitals in the country to offer patients the opportunity to have brain surgery using technology that reduced the need for follow-up surgery. Now, its neurosurgery team has reached a milestone by performing more than 1,000 cases using its moveable intraoperative MRI system – more than any other center in the United States. St. Louis (PRWEB) May 20, 2014 Barnes-Jewish Hospital was one of the first hospitals in the country to offer patients the...

2014-05-19 12:27:37

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cancer Profiling and Pathways: Technologies and Global Marketshttp://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.htmlSTUDY GOALS AND OBJECTIVESThis BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and...

2014-05-19 10:21:58

University of Cincinnati Academic Health Center About one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it. This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important. These findings are published in the May 16, 2014 edition of the journal PLOS ONE....

herpes virus attack a brain tumor cell
2014-05-18 03:00:47

Harvard Stem Cell Institute (HSCI) Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat. The work, led by Khalid...

2014-05-16 08:26:45

DUBLIN, May 16, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/6mvft5/circulating_tumor) has announced the addition of the "Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related